Shanghai Guotou Xiandao, Enhua Pharmaceutical, Baili Tianheng Form RMB 217 Million Defu Venture Fund
Recently, Shanghai Defu Venture Capital Fund Partnership (Limited Partnership) was established with a capital contribution of approximately RMB 217 million. Its business scope includes venture capital (limited to investing in unlisted enterprises). Business registration information shows that the partnership is jointly held by Shanghai Guotou Xiandao Biopharmaceutical Private Equity Fund Partnership (Limited Partnership), Enhua Pharmaceutical, Baili Tianheng (Shanghai) Biopharmaceutical Technology Co. , Ltd. , and others.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is positive for Biotechnology, with intensity 40/100 and 60% confidence over a medium term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.